Carotid Artery Stenosis Clinical Trial
— SERIC-CASCEAOfficial title:
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Carotid Artery Stenosis Receiving Carotid EndArterectomy: A Pilot, Randomized Controlled Trial
The purpose of this study is to explore the safety and efficacy of remote ischemic conditioning in patients with carotid artery stenosis receiving carotid endarterectomy.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | March 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age=18 years, <80 years, regardless of sex; 2. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the degree of stenosis should more than 50% (Based on North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET) Criteria), in asymptomatic patients the degree of stenosis should more than 70% (Based on NASCET Criteria); 3. Baseline mRS 0-2; 4. Can cooperate with and complete brain magnetic resonance imaging (MRI) examination; 5. Signed and dated informed consent is obtained; Exclusion Criteria: 1. Evolving stroke; 2. Chronic complete occlusion of the carotid artery without obvious symptoms of cerebral ischemia; 3. Severe dementia; 4. The causes of cardiogenic embolism, such as rheumatic mitral or aortic valve stenosis, artificial heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombosis or valve tumor, congestive heart failure, bacterial endocarditis, etc; 5. Uncontrolled hypertension (defined as systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mmHg, despite medication taken at enrollment); 6. Severe hepatic and renal dysfunction (defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =3 times higher than the upper limit of the normal range, creatinine >265umol/l (3mg/dl)); 7. The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 8. Pregnant or lactating women; 9. He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; 10. Other conditions that the researchers think are not suitable for the group. |
Country | Name | City | State |
---|---|---|---|
China | The First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Yi Yang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who got =1 new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. | Patients underwent magnetic resonance imaging (including DWI)at baseline and 6 days after randomization. | 6 days | |
Secondary | The number of new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. | Patients underwent magnetic resonance imaging (including DWI)at baseline and 6 days after randomization. | 6 days | |
Secondary | The volume of new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. | Patients underwent magnetic resonance imaging(including DWI) at baseline and 6 days after randomization. | 6 days | |
Secondary | Number of patients with cerebrovascular events, cardiovascular events or death. | Cerebrovascular events included ischemic stroke, transient ischemic attack (TIA), cerebral hemorrhage. Cardiovascular events included angina and myocardial infarction. Death included any reason caused death. | 90±7 days | |
Secondary | Proportion of patients with any side effects of Remote ischemic conditioning (RIC) treatment. | The side effects referred to any side effects of RIC or sham RIC treatment, not including the sides effect of medications and Carotid Endarterectomy (CEA). | 6 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931161 -
Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)
|
Phase 4 | |
Recruiting |
NCT03353103 -
Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy
|
Phase 2 | |
Completed |
NCT03996148 -
Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques
|
Phase 4 | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Completed |
NCT00318851 -
Carotid Artery Stenting With Protection Registry
|
Phase 3 | |
Completed |
NCT00597974 -
Neurological Outcome With Carotid Artery Stenting
|
N/A | |
Active, not recruiting |
NCT05293067 -
Troponin In Carotid Revascularization
|
||
Completed |
NCT03133429 -
Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.
|
N/A | |
Recruiting |
NCT01440036 -
The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque
|
N/A | |
Completed |
NCT00417963 -
ViVEXX Carotid Revascularization Trial (VIVA)
|
Phase 3 | |
Completed |
NCT00177346 -
A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection
|
N/A | |
Recruiting |
NCT05574972 -
Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial)
|
N/A | |
Recruiting |
NCT02476396 -
Structural Stability of Carotid Plaque and Symptomatology
|
||
Completed |
NCT05451485 -
VFI in Healthy Vessels
|
||
Not yet recruiting |
NCT02224209 -
Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis
|
Phase 4 | |
Completed |
NCT02006095 -
Neuroimaging Correlates of Memory Decline Following Carotid Interventions
|
||
Terminated |
NCT01236508 -
Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
|
Phase 4 | |
Recruiting |
NCT05126238 -
A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction
|
Phase 3 | |
Recruiting |
NCT06170580 -
Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging
|
||
Recruiting |
NCT05800821 -
Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning
|